EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 128 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma ESMO Calls for Cancer Care Integration in EU Global Health Resilience Initiative (GHRI) MOST POPULAR Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal September 24, 2020 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Medicare Open Enrollment Starts Tomorrow! October 14, 2021 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Load more HOT NEWS Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or... EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.”
